These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37983217)

  • 1. Burden of elevated lipoprotein(a) among patients with atherosclerotic cardiovascular disease: Evidence from a systematic literature review and feasibility assessment of meta-analysis.
    Orfanos P; Fonseca AF; Hu X; Gautam R; Montgomery G; Studer R; Kaur J; Saxena N; Kaushik N
    PLoS One; 2023; 18(11):e0294250. PubMed ID: 37983217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank.
    Welsh P; Al Zabiby A; Byrne H; Benbow HR; Itani T; Farries G; Costa-Scharplatz M; Ferber P; Martin L; Brown R; Fonseca AF; Sattar N
    Atherosclerosis; 2024 Feb; 389():117437. PubMed ID: 38219651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States.
    Fonseca AF; Byrne H; Laguna A; Itani T; Studer R; Heo J; Dillon A; Ferber P; Costa-Scharplatz M
    J Manag Care Spec Pharm; 2023 May; 29(5):519-529. PubMed ID: 37121256
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.
    Small AM; Pournamdari A; Melloni GEM; Scirica BM; Bhatt DL; Raz I; Braunwald E; Giugliano RP; Sabatine MS; Peloso GM; Marston NA; Natarajan P
    JAMA Cardiol; 2024 Apr; 9(4):385-391. PubMed ID: 38353970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease.
    Berman AN; Biery DW; Besser SA; Singh A; Shiyovich A; Weber BN; Huck DM; Divakaran S; Hainer J; Kaur G; Blaha MJ; Cannon CP; Plutzky J; Januzzi JL; Booth JN; López JAG; Kent ST; Nasir K; Di Carli MF; Bhatt DL; Blankstein R
    J Am Coll Cardiol; 2024 Mar; 83(9):873-886. PubMed ID: 38418000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
    Puri R; Nissen SE; Arsenault BJ; St John J; Riesmeyer JS; Ruotolo G; McErlean E; Menon V; Cho L; Wolski K; Lincoff AM; Nicholls SJ
    JAMA Cardiol; 2020 Oct; 5(10):1136-1143. PubMed ID: 32639518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Elevated Lipoprotein A on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
    Sinha T; Guntha M; Mayow AH; Zin AK; Chaudhari SS; Khan MW; Kholoki S; Khan A
    Cureus; 2024 May; 16(5):e61069. PubMed ID: 38915979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review.
    Cherepanov D; Bentley TGK; Hsiao W; Xiang P; O'Neill F; Qian Y; Yurgin N; Beenhouwer D
    Curr Med Res Opin; 2018 Mar; 34(3):459-473. PubMed ID: 29105492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease.
    Verweij SL; de Ronde MWJ; Verbeek R; Boekholdt SM; Planken RN; Stroes ESG; Pinto-Sietsma SJ
    J Clin Lipidol; 2018; 12(3):597-603.e1. PubMed ID: 29550494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.
    Wong ND; Fan W; Hu X; Ballantyne C; Hoodgeveen RC; Tsai MY; Browne A; Budoff MJ
    J Am Coll Cardiol; 2024 Apr; 83(16):1511-1525. PubMed ID: 38631771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy.
    Waissi F; Dekker M; Timmerman N; Hoogeveen RM; van Bennekom J; Dzobo KE; Schnitzler JG; Pasterkamp G; Grobbee DE; de Borst GJ; Stroes ESG; de Kleijn DPV; Kroon J
    Stroke; 2020 Oct; 51(10):2972-2982. PubMed ID: 32878565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma lipoprotein(a) measured in the routine clinical care is associated to atherosclerotic cardiovascular disease during a 14-year follow-up.
    Littmann K; Hagström E; Häbel H; Bottai M; Eriksson M; Parini P; Brinck J
    Eur J Prev Cardiol; 2022 Feb; 28(18):2038-2047. PubMed ID: 34343284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding very high lipoprotein(a): the need for routine assessment.
    Nurmohamed NS; Kaiser Y; Schuitema PCE; Ibrahim S; Nierman M; Fischer JC; Chamuleau SAJ; Knaapen P; Stroes ESG
    Eur J Prev Cardiol; 2022 May; 29(5):769-776. PubMed ID: 34632502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.
    Nissen SE; Wolski K; Cho L; Nicholls SJ; Kastelein J; Leitersdorf E; Landmesser U; Blaha M; Lincoff AM; Morishita R; Tsimikas S; Liu J; Manning B; Kozlovski P; Lesogor A; Thuren T; Shibasaki T; Matei F; Silveira FS; Meunch A; Bada A; Vijan V; Bruun NE; Nordestgaard BG;
    Open Heart; 2022 Oct; 9(2):. PubMed ID: 36252994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Lipoprotein (a) Levels on Long-term Cardiovascular Outcomes in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries.
    Gao S; Ma W; Huang S; Lin X; Yu M
    Am J Cardiol; 2021 Aug; 152():34-42. PubMed ID: 34130824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
    Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotics for secondary prevention of coronary heart disease.
    Sethi NJ; Safi S; Korang SK; Hróbjartsson A; Skoog M; Gluud C; Jakobsen JC
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD003610. PubMed ID: 33704780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.